BB Biotech's Q3 2025 Outperformance Amid Sector Recovery

BB Biotech reported a strong third quarter for 2025 with both its share price and Net Asset Value (NAV) outperforming the Nasdaq Biotechnology Index (NBI). The company's share prices rose by over 19% in USD, surpassing the NBI's gains of 15.6%. NAV increased by 23.5% in USD, indicating a significant outperformance compared to the benchmark. This growth was supported by the US Federal Reserve's rate cut and diminishing inflation which improved financing conditions and risk appetite.

The sector's recovery was also bolstered by strategic M&A activities, with significant transactions recorded, including those by Pfizer and Roche. Furthermore, BB Biotech expanded its portfolio with new investments in Avidity Biosciences, focusing on RNA-based therapeutics.

With a net profit of CHF 448 million, BB Biotech expects further progress in the sector. The company remains dedicated to responsible investing and long-term value creation.